Clinical review report: Ustekinumab (Stelara/Stelara I.V.) Janssen Inc. indication: treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies
This review aims to evaluate the beneficial and harmful effects of ustekinumab IV infusion (induction phase) and subcutaneous injection (maintenance phase) for the treatment of adult patients with moderately to severely active ulcerative colitis who have failed or were intolerant to treatment with i...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, September 2020
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This review aims to evaluate the beneficial and harmful effects of ustekinumab IV infusion (induction phase) and subcutaneous injection (maintenance phase) for the treatment of adult patients with moderately to severely active ulcerative colitis who have failed or were intolerant to treatment with immunomodulators or corticosteroids -- but never failed treatment with a biologic -- or have failed or were intolerant to treatment with a biologic |
|---|---|
| Physical Description: | 1 PDF file (121 pages) illustrations |